The evaluation and management of the acutely agitated elderly patient

Mount Sinai Journal of Medicine

Volumn 73, Issue 7, 2006, Pages 976-984

  Nassisi, Denise ^a   Korc, Beatriz ^a   Hahn, Sigrid ^a   Bruns Jr , John ^a   Jagoda, Andy ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

Agitation; Antipsychotics; Benzodiazepines; Delirium; Geriatrics

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; DIAZEPAM; DROPERIDOL; GLUCOSE; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; OXYGEN; PARACETAMOL; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

AGITATION; AKATHISIA; ANTICHOLINERGIC EFFECT; ATTENTION DISTURBANCE; BLOOD ANALYSIS; BLOOD PRESSURE; BRADYKINESIA; CHOREOATHETOSIS; CLINICAL EXAMINATION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS DISORDER; DEHYDRATION; DELIRIUM; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG FATALITY; DRUG HALF LIFE; DRUG WITHDRAWAL; DYSTONIA; ELDERLY CARE; ELECTROLYTE DISTURBANCE; ENTEROPATHY; EXTRAPYRAMIDAL SYMPTOM; GERONTOPSYCHIATRY; HEALTH STATUS; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOXIA; INFECTION; KIDNEY FAILURE; LIVER FAILURE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEMORY DISORDER; MENTAL HEALTH; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; ORGANIC BRAIN SYNDROME; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PSYCHOLOGIC TEST; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEPSIS; SIDE EFFECT; SUBSTANCE ABUSE; SYMPTOM; TARDIVE DYSKINESIA; TORSADE DES POINTES; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HALOPERIDOL; HUMANS; PHYSICAL EXAMINATION; PSYCHOMOTOR AGITATION; RISK FACTORS;

EID: 33845971886     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. www.census.gov/populations/nation/summaryno-t5-ftxt. December 2003.
2. McCaig LF, Burt CW. National Hospital Ambulatory Medical Care Survey: 2003 emergency department summary. Advance data from vital and health statistics; no. 358. Hyattsville (MD): National Center for Health Statistics; 2005.
3. Strange GR, Chen EH, Sanders AB. Use of emergency departments by elderly patients: projections from a multi-center data base. Ann Emerg Med 1992; 21(7):819-824.
4. Naughton BJ, Moran MB, Kadah H, et al. Delirium and other cognitive impairment in older adults in the emergency department. Ann Emerg Med 1995; 25:751-755.
5. Levkoff SE, Besdine RW, Wetle T. Acute confusional states (delirium) in the hospitalized elderly. Ann Rev Gerontol Geriatr 1986; 6:1-26.
6. Inouye S, Rushing J, Foreman M, et al. Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. J Gen Intern Med 1998; 13:234-242.
7. Pompei P, Foreman M, Rudberg M, et al. Delirium in hospitalized older persons: outcome and predictors. J Am Geriatr Soc. 1994; 42:809-815.
8. Dolan MM, Hawkes WG, Zimmerman SI, et al. Delirium on hospital admission in aged hip fracture patients: prediction of mortality and 2-year functional outcomes. J Gerontol A Biol Sci Med Sci 2000; 55(9):M527-M534.
9. American Psychiatric Association, diagnostic and statistical manual, 4th edition, Washington (DC): APA Press; 1994.
10. Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA 1990; 263(8):1097-1101.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(13):189-198.
12. Nelson A, Fogel BS, Faust D. Bedside cognitive screening instruments: a critical assessment. J Nerv Ment Dis 1986; 174(2)5:73-83.
13. Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990; 113(12):941-948.
14. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers Criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163(22):2716-2724.
15. American College of Emergency Physicians. Clinical policy for the initial approach to patients presenting with altered mental status. Ann Emerg Med 1999; 33(2):251-281.
16. Hoffman JR, Schriger DL, Votey SR, Luo JS. The empiric use of hypertonic dextrose in patients with altered mental status: a reappraisal. Ann Emerg Med 1992; 21(1):20-24.
17. Naughton B, Moran M, Ghaly Y, Michalakes C. Computed tomography scanning and delirium in elder patients. Acad Emerg Med 1997; 4:1107-1110.
18. Koponen H, Hurri L, Stenback U, et al. Computed tomography findings in delirium. J Nerv Ment Dis 1989; 177(4):226-231.
19. Elie M, Cole M, Premeau F, Bellavance F. Delirium risk factors in elderly hospitalized patients. J Gen Intern Med 1998; 14:204-212.
20. McCusker J, Cole M, Abrahamowicz M, et al. Environmental risk factors for delirium in hospitalized older people. J Am Geriatr Soc 2001; 49:1327-1334.
21. Lundstrom M, Edlund A, Karlsson S, et al. A multifactorial intervention program reduces the duration of delirium, length of hospitalization, and mortality in delirious patients. J Am Geriatr Soc 2005; 53(4):622-628.
22. Cotter VT. Restraint free care in older adults with dementia. Keio J Med 2005; 54(2):80-84.
23. Lynch E, Lazor M, Gellis J, et al. The impact of postoperative pain on the development of postoperative delirium. Anesth Analg 1998; 86:781-785.
24. Duggleby W, Lander J. Cognitive status and postoperative pain: older adults. J Pain Symptom Manage 1994; 9(1):19-27.
25. Morrison R, Magaziner J, Gilbert M, et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci 2003; 58:76-81.
26. Allen M. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000; 61:11-20.
27. American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999; 156(Suppl):1-20.
28. Clinton JE, Sterner S, Stelmachera Z, Ruiz E. Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med March 1987; 16:319-322.
29. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153(2):231-237.
30. Lonegran E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002852. D0I: 10.1002/14651858.CD002852.
31. Thomas H, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med 1992; 21:407-413.
32. Resnick M, Burton BT. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 1984; 45(7):298-299.
33. Richards JR, Derlet RW, Duncan DR. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med 1998; 16:567-573.
34. Chase PB, Biros MH. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med 2002; 9:1402-1410.
35. Kao L, Kirk M, Evers S, Rosenfeld S. Droperidol, QT prolongation and sudden death: what is the evidence? Ann Emerg Med 2003; 41:546-558.
36. Horowitz B, Bizovi K, Morena R. Droperidol - behind the black box warning. Acad Emerg Med 2002; 9:615-618.
37. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119(5):391-394.
38. Sharma N, Rosman H, Padhi D, Tisdale J. Tosades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81:238-240.
39. Jackson T, Ditmanson L, Phibba B. Torsades de pointes and low-dose oral haloperidol. Arch Intern Med 1997; 157:2013-2015.
40. FDA Public Health Advisory April 11, 2005 www.fda.gov/med-watch/report/ hcp.htm [accessed 7/13/06]
41. Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005; 293(20):2462.
42. Lieberman J, Stroup T, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
43. Alexopoulos G, Jeste D, Chun H, et al. Postgraduate Medicine. A Special Report. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. McGraw-Hill Companies. Jan 2005.
44. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's Disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU study group. Arch Gen Psychiatry 2000; 57:968-976.
45. Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001; 16 Suppl 1:S62-S70.
46. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without behavioral disturbances in patients with Alzheimer' disease. Int J Geriatr Psychiatry 2004; 19(2):115-126.
47. Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003; 21:192-198.
48. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26:494-504.
49. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 2001; 155:128-134.
50. Greco KE, Tune LE, Brown FW, Van Horn WA. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. J Clin Psychiatry 2005; 66(7):928-929.
51. Oechsner M, Korchounov A. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? Hum Psychopharmacol 2005; 20(3):203-205.
52. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60(2):107-115.
53. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo, controlled trial of risperidone for the treatment pf agitation and psychosis of dementia. J. Clin Psychiatry 2003; 64(2):134-143.
54. Suh GH, Son HG, Ju YS, et al. A randomized, double-blind, cross-over comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004; 12(5):509-516.
55. Liu CY, Juang YY, Liang HY, et al. Efficacy of risperidone in treating the hyperactive symptoms of delirium. Int Clin Psychopharmacol 2004; 19(3):165-168.
56. Nobay F, Simon BC, Levitt MA, Dresden GM. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med 2004; 11(7):744-749.
57. Martel M, Sterzinger A, Miner J, et al. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med 2005; 12(12):1167-1172. Erratum in: Acad Emerg Med. 2006;13(2):233.
58. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52:177-180.
59. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15:335-340.
60. Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988; 18(2):365-374.
61. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262(23):3303-3307.
62. Salzman C, Fisher J, Nobel K, et al. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry 1992; 7:89-93.
63. Christe C, Janssens J. Armenian B, et al. Midazolam sedation for upper gastrointestinal endoscopy in older persons: a randomized, double-blind, placebo-controlled study. J Am Geriatr Soc 2000; 48(11):1398-1403.
64. Fredman B, Lahav M, Zohav E, et al. The effect or midazolam premedication on mental and psychomotor recovery in geriatric patients undergoing brief surgical procedures. Anesth Analg 1999; 89(5):1161-1166.
65. Oei-Lim VL, Kalkman CJ, Bartelsman JF, et al. Cardiovascular responses, arterial oxygen saturation and plasma catecholamine concentration during upper gastrointestinal endoscopy using conscious sedation with midazolam or propofol. Eur J Anaesthesiol 1998; 15(5):535-543.
66. Dhariwal A, Plevris J, Lo N, et al. Age, anemia and obesity-associated oxygen desaturation during upper gastrointestinal endoscopy. Gastrointest Endosc 1992; 38(6):684-688.
67. Fulton S, Mullen K. Completion of upper endoscopic procedures despite paradoxical reaction to midazolam: a role for flumazenil? Am J Gastroenterol 2000; 95:809-811.
68. Robin C, Trieger N. Paradoxical reactions to benzodiazepines in intravenous sedation: a report of two cases and review of the literature. Anesth Prog 2002; 49:128-132.